INS and diabetes mellitus: Based on the inhibition of glucose reabsorption from pre-urine, the glucose-lowering effect of SGLT2-Is only occurs in a hyperglycemic/glycosuric state and, compared to other therapeutic strategies for diabetes, through an action independent of insulin, they are not affected by the deterioration of β-cell function or insulin sensitivity, nor associated with a hypoglycemic risk, even in non-diabetic subjects [14].